Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 145-162 , March 2007

Biotherapy

  • U. Plöckinger, MD (Senior Consultant, Interdisziplinary Centre of Metabolism:Endocrinology, Diabetes and Metabolism)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 30 450 553 552; Fax: +49 30 450 7553 552.
  • B. Wiedenmann, MD (Professor of Gastroenterology and Head of the Department of Hepatology and Gastroenterology)

References 

  1. Plockinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80(6):394–424
  2. Venkatesh S, Ordonez NG, Ajani J, et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer. 1990;65(2):354–357
  3. Lo CY, van Heerden JA, Thompson GB, et al. Islet cell carcinoma of the pancreas. World J Surg. 1996;20(7):878–883discussion 884
  4. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25(3):458–511
  5. Makridis C, Rastad J, Oberg K, et al. Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors. World J Surg. 1996;20(7):900–906discussion 907
  6. Bax ND, Woods HF, Batchelor A, et al. Clinical manifestations of carcinoid disease. World J Surg. 1996;20(2):142–146
  7. Moertel CG. Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol. 1987;5(10):1502–1522
  8. Creutzfeldt W. Carcinoid tumors: development of our knowledge. World J Surg. 1996;20(2):126–131
  9. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer. 1997;79(4):813–829
  10. Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet. 1998;352(9130):799–805
  11. Oberg K. The use of chemotherapy in the management of neuroendocrine tumors. Endocrinol Metab Clin North Am. 1993;22(4):941–952
  12. Oberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol. 1993;5(1):110–120
  13. Ahlman H, Westberg G, Wangberg B, et al. Treatment of liver metastases of carcinoid tumors. World J Surg. 1996;20(2):196–202
  14. Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg. 1995;28:317–336
  15. Reisine T, Bell GI. Molecular properties of somatostatin receptors. Neuroscience. 1995;67(4):777–790
  16. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–198
  17. Bruns C, Weckbecker G, Raulf F, et al. Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994;733:138–146
  18. Reubi JC, Kappeler A, Waser B, et al. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J Clin Endocrinol Metab. 1998;83(10):3746–3749
  19. Kimura N, Pilichowska M, Date F, et al. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res. 1999;5(11):3483–3487
  20. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47
  21. Liebow C, Lee MT, Schally A. Antitumor effects of somatostatin mediated by the stimulation of tyrosine phosphatase. Metabolism. 1990;39(9 Supplement 2):163–166
  22. Pan MG, Florio T, Stork PJ. G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science. 1992;256(5060):1215–1217
  23. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 1988;48(24 Pt 1):6977–6985
  24. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12(4):450–482
  25. Cordelier P, Esteve JP, Bousquet C, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A. 1997;94(17):9343–9348
  26. Todisco A, Seva C, Takeuchi Y, et al. Somatostatin inhibits AP-1 function via multiple protein phosphatases. Am J Physiol. 1995;269(1 Pt 1):G160–G166
  27. Koizumi M, Onda M, Tanaka N, et al. Antiangiogenic effect of octreotide inhibits the growth of human rectal neuroendocrine carcinoma. Digestion. 2002;65(4):200–206
  28. Imam H, Eriksson B, Lukinius A, et al. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. Acta Oncol. 1997;36(6):607–614
  29. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther. 2004;102(1):61–85
  30. Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–716
  31. Hillman N, Herranz L, Alvarez C, et al. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes. 1998;106(3):226–230
  32. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Digestive Diseases and Sciences. 1989;34(3 supplement):14S–27S
  33. Kvols LK, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. The New England Journal of Medicine. 1986;315(11):663–666
  34. Tomassetti P, Migliori M, Gullo L. Slow-release lanreotide treatment in endocrine gastrointestinal tumors. Am J Gastroenterol. 1998;93(9):1468–1471
  35. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors–the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21(14):2689–2696
  36. Tomassetti P, Migliori M, Corinaldesi R, et al. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000;14(5):557–560
  37. Ruszniewski P, et al. Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients. Gut. 1996;39(2):279–283
  38. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88(4):770–776
  39. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol. 2000;23(4):412–415
  40. Wymenga AN, Eriksson B, Salmela PI, et al. Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol. 1999;17(4):1111
  41. Ruszniewski P, et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinology. 2004;80(4):244–251
  42. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Annals of Oncology. 1999;10(supplement 2):S31–S38
  43. Maton PN. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterology Clinics of North America. 1989;18(4):897–922
  44. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38(3):430–438
  45. Scherubl H, et al. Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide. European Journal of Cancer. 1994;30A(10):1590–1591
  46. Ruskone A, et al. Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera. Digestive Diseases and Sciences. 1982;27(5):459–466
  47. O'Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinology and Metabolism Clinics of North America. 1989;18(2):545–556
  48. Santangelo WC, et al. Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Annals of Internal Medicine. 1985;103(3):363–367
  49. Rosenbaum A, et al. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion. 1989;42(2):116–120
  50. Ch'ng JL, et al. Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production. The American Journal of Medicine. 1985;79(1):135–138
  51. Creutzfeldt W, et al. Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger–Ellison syndrome). Human Pathology. 1975;6(1):47–76
  52. Ruszniewski P, et al. Long-acting somatostatin (SMS 201-995) in the management of Zollinger–Ellison syndrome: evidence for sustained efficacy. Pancreas. 1988;3(2):145–152
  53. Vinik AI, et al. Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery. 1988;104(5):834–842
  54. Wulbrand U, et al. Growth factor receptor expression in human gastroenteropancreatic neuroendocrine tumours. European Journal of Clinical Investigation. 1998;28(12):1038–1049
  55. Nauck C, et al. 111In-pentetreotide (somatostatin analogue) scintigraphy as an imaging procedure for endocrine gastro-entero-pancreatic tumors. Zeitschrift für Gastroenterologie. 1994;32(6):323–327
  56. Rubin J, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. Journal of Clinical Oncology. 1999;17(2):600–606
  57. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs. 1994;5(5):503–519
  58. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993;72(1):244–248
  59. Panzuto F, Di Fonzo M, Iannicelli E, et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17(3):461–466
  60. Faiss S, Scherubl H, Riecken EO, et al. Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system. Recent Results Cancer Res. 1996;142:193–207
  61. Welin SV, Janson ET, Sundin A, et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur J Endocrinol. 2004;151(1):107–112
  62. Faiss S, Rath U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion. 1999;60(5):469–476
  63. Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol. 2005;3(8):761–771
  64. Hussaini SH, Murphy GM, Kennedy C, et al. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology. 1994;107(5):1503–1513
  65. Bigg-Wither GW, Ho KK, Grunstein RR, et al. Effects of long term octreotide on gall stone formation and gall bladder function. Bmj. 1992;304(6842):1611–1612
  66. Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer. 1997;79(4):830–834
  67. Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J Clin Endocrinol Metab. 1990;71(6):1658–1662
  68. Plockinger U, Perez-Canto A, Emde C, et al. Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly. Eur J Endocrinol. 1998;139(4):387–394
  69. Funa K, Eriksson B, Wilander E, et al. In situ hybridization study of chromogranin A and B mRNA in carcinoid tumors. Histochemistry. 1991;95(6):555–559
  70. Grander D, Oberg K, Lundqvist ML, et al. Interferon-induced enhancement of 2',5'-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 1990;336(8711):337–340
  71. Oberg K, Eriksson B. The role of interferons in the management of carcinoid tumours. Br J Haematol. 1991;79(Supplement 1):74–77
  72. Oberg K. The action of interferon alpha on human carcinoid tumours. Semin Cancer Biol. 1992;3(1):35–41
  73. Oberg K, Eriksson B, Janson ET. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors. Digestion. 1994;55(Supplement 3):64–69
  74. Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology. 2000;118(4):735–748
  75. Anderson PM, Katsanis E, Leonard AS, et al. Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. Cancer Res. 1990;50(6):1853–1856
  76. Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors–an antiangiogenic effect?. Anticancer Drugs. 1996;7(2):175–181
  77. Andersson T, Wilander E, Eriksson B, et al. Effects of interferon on tumor tissue content in liver metastases of human carcinoid tumors. Cancer Res. 1990;50(11):3413–3415
  78. Brosjo O, Bauer HC, Brostrom LA, et al. Growth inhibition of human osteosarcomas in nude mice by human interferon-alpha: significance of dose and tumor differentiation. Cancer Res. 1987;47(1):258–262
  79. Biesma B, Willemse PH, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer. 1992;66(5):850–855
  80. Jacobsen MB, Hanssen LE, Kolmannskog F, et al. Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol. 1995;30(8):789–796
  81. Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann Oncol. 2001;12(Supplement 2):S111–S114
  82. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19(4):617–636
  83. Eriksson B, Oberg K, Alm G, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet. 1986;2(8519):1307–1309
  84. Tiensuu Janson EM, Ahlstrom H, Andersson T, et al. Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer. 1992;28A(10):1647–1650
  85. Smith DB, Scarffe JH, Wagstaff J, et al. Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor. Cancer Treat Rep. 1987;71(12):1265–1266
  86. Doberauer C, Mengelkoch B, Kloke O, et al. Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha. Acta Oncol. 1991;30(5):603–605
  87. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol. 1989;7(7):865–868
  88. Creutzfeldt W, Bartsch HH, Jacubaschke U, et al. Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide. Acta Oncol. 1991;30(4):529–535
  89. Oberg K. Neuroendocrine gastrointestinal tumours. Ann Oncol. 1996;7(5):453–463
  90. Veenhof CH, de Wit R, Taal BG, et al. A dose-escalation study of recombinant interferon-alpha in patients with a metastatic carcinoid tumour. Eur J Cancer. 1992;28(1):75–78
  91. Nobin A, Lindblom A, Mansson B, et al. Interferon treatment in patients with malignant carcinoids. Acta Oncol. 1989;28(3):445–449
  92. Ronnblom LE, Alm GV, Oberg K. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol. 1991;30(4):537–540
  93. Nold R, Frank M, Kajdan U, et al. Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha. Z Gastroenterol. 1994;32(4):193–197
  94. Fjallskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer. 2001;92(5):1101–1107
  95. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001;37(8):1014–1019
  96. di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer. 1996;77(2):402–408
  97. Arnold R, Neuhaus C, Benning R, et al. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J Surg. 1993;17(4):511–519
  98. Arnold R, Benning R, Neuhaus C, et al. Gastroenteropancreatic endocrine tumours: effect of Sandostatin on tumour growth. The German Sandostatin Study Group.. Digestion. 1993;54(Suppl. 1):72–75
  99. Ducreux M, Ruszniewski P, Chayvialle JA, et al. The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors. Am J Gastroenterol. 2000;95(11):3276–3281
  100. Eriksson B, Renstrup J, Imam H, et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann Oncol. 1997;8(10):1041–1044
  101. Anthony L, Johnson D, Hande K, et al. Somatostatin analogue phase I trials in neuroendocrine neoplasms. Acta Oncol. 1993;32(2):217–223
  102. Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann Oncol. 1992;3(8):635–638
  103. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst. 1989;81(7):531–535
  104. Schober C, Schmoll E, Schmoll HJ, et al. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer. 1992;28A(10):1664–1666

PII: S1521-690X(07)00003-6

doi: 10.1016/j.beem.2007.01.002

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 21, Issue 1 , Pages 145-162 , March 2007

Article Tools